NASDAQ · Biotechnology
Cardio Diagnostics Holdings Inc. (CDIO) Stock
$1.87
+0.54%
NASDAQ: CDIO
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cardio Diagnostics Holdings (CDIO) Showcases Precision Cardiovascular Solutions for Employers, Health Plans
NewMediaWire · Jul 1, 2026
Cardio Diagnostics Holdings (CDIO) Leverages Epigenetics to Reveal Hidden Heart Disease Risks
NewMediaWire · Jun 30, 2026
Cardio Diagnostics Holdings (CDIO) Brings Molecular Precision to a Blind Spot in Coronary Heart Disease Detection
NewMediaWire · Jun 29, 2026
Cardio Diagnostics Holdings (CDIO) Expands Coverage of Precision Cardiovascular Tests Through Atlas Healthcare Physicians
NewMediaWire · Jun 25, 2026
Atlas Healthcare Physicians to Cover Cardio Diagnostics’ Precision Cardiovascular Medicine Tests Across Its Network
Business Wire · Jun 24, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held8.31%
Institutions Held9.34%
Institutions Float Held10.18%
Peer Comparison
About Cardio Diagnostics Holdings Inc.
Cardio Diagnostics Holdings Inc. is led by CEO Meeshanthini V. Dogan, employs 13 people, headquartered in US, publicly traded since 2022.
Cardio Diagnostics Holdings Inc. (CDIO) stock trades at $1.87 with a market capitalization of $5.53M. The stock is valued at a price-to-earnings (P/E) ratio of -0.71, price-to-book of 0.82, price-to-sales of 421.90. Over the past 52 weeks the stock has ranged between $0.97 and $7.91, and currently trades 76.4% below its 52-week high.
On profitability, Cardio Diagnostics Holdings Inc. generates a return on equity (ROE) of -82.27%, return on capital employed of -85.34%, an operating margin of -400.75%, a net profit margin of -401.52%.